Fulgent Genetics, Inc.(FLGT)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Rank #2,734 of 2,961 stocks
Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.
Revenue Growth
Profitability
Balance Sheet
Earnings Quality
Free Cash Flow
Institutional Flow
Revenue Scale
Dilution Risk
FLGT Stock Analysis & AI Quality Score
Data updated 2026-09-11AI stock analysis and institutional research for Fulgent Genetics, Inc. (FLGT), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores FLGT at 23.1/100 on a 32-signal composite quality model, placing it at rank #2,734 of 2,961 stocks — the bottom half of the AI-ranked universe. Areas of concern include institutional flow (9.2) and earnings quality (10.5), which score below median versus the broader universe. Shareholder dilution risk is elevated at 14.2/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), Fulgent Genetics, Inc. reports quarterly revenue of $85.4M, net income of $-29.5M, an operating margin of -42.3%. Top institutional holders of FLGT by reported 13-F value include BlackRock, ACADIAN ASSET MANAGEMENT, VANGUARD CAPITAL MANAGEMENT, based on the most recent SEC filings. FLGT trades on the Nasdaq exchange and files with the SEC under CIK 1674930. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate FLGT daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Fulgent Genetics, Inc. directly from SEC EDGAR. Fulgent Genetics, Inc.'s 13F Pro composite quality score has ranged between 21 and 86 since 2021, currently 23.1 — a declining long-term trajectory across 68 quarterly and live scoring snapshots.
Revenue
Q2 2026
$85.4M
Net Income
Q2 2026
$-29.5M
Free Cash Flow
Q2 2026
$-27.6M
Operating Margin
Q2 2026
-42.3%
ROIC
Q2 2026
-14.4%
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · ProRevenue
+13.8% YoYNet Income
-41.7% YoYOperating Income
-23.2% YoYTotal Assets
-0.5% YoYOp. Cash Flow
-582.6% YoYFree Cash Flow
-545.1% YoY| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $322.7M +13.8% | $283.5M -2.0% | $289.2M -53.3% | $619.0M -37.6% | $992.6M +135.4% | $421.7M |
| Net Income | $-60.5M -41.7% | $-42.7M +74.6% | $-167.8M -217.0% | $143.4M -71.7% | $507.4M +136.7% | $214.3M |
| Operating Income | $-91.1M -23.2% | $-73.9M +62.2% | $-195.5M -209.5% | $178.5M -73.6% | $676.0M +133.0% | $290.2M |
| Total Assets | $1.21B -0.5% | $1.22B -1.2% | $1.24B -10.9% | $1.39B +8.4% | $1.28B +82.6% | $700.5M |
| Operating Cash Flow | $-101.6M -582.6% | $21.1M -22.0% | $27.0M -89.3% | $253.5M -52.9% | $538.6M +283.0% | $140.6M |
| Free Cash Flow | $-124.2M -545.1% | $-19.3M -501.5% | $4.8M -98.0% | $234.7M -54.4% | $514.8M +387.9% | $105.5M |
Get alerted when FLGT's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for Fulgent Genetics, Inc. including:
Top Institutional Holders of FLGT
BlackRock, Inc.
$46.9M2,286,669 shACADIAN ASSET MANAGEMENT LLC
$20.9M1,017,913 shVANGUARD CAPITAL MANAGEMENT LLC
$16.2M789,498 shJACOBS LEVY EQUITY MANAGEMENT, INC
$16.0M782,116 shJPMORGAN CHASE & CO
$15.5M756,558 shDiametric Capital, LP
$14.3M697,784 shAMERIPRISE FINANCIAL INC
$13.8M670,084 shDIMENSIONAL FUND ADVISORS LP
$12.8M625,355 shGEODE CAPITAL MANAGEMENT, LLC
$10.7M521,014 shSTATE STREET CORP
$10.2M498,673 sh
| Fund | Value | Shares |
|---|---|---|
| BlackRock, Inc. | $46.9M | 2,286,669 |
| ACADIAN ASSET MANAGEMENT LLC | $20.9M | 1,017,913 |
| VANGUARD CAPITAL MANAGEMENT LLC | $16.2M | 789,498 |
| JACOBS LEVY EQUITY MANAGEMENT, INC | $16.0M | 782,116 |
| JPMORGAN CHASE & CO | $15.5M | 756,558 |
| Diametric Capital, LP | $14.3M | 697,784 |
| AMERIPRISE FINANCIAL INC | $13.8M | 670,084 |
| DIMENSIONAL FUND ADVISORS LP | $12.8M | 625,355 |
| GEODE CAPITAL MANAGEMENT, LLC | $10.7M | 521,014 |
| STATE STREET CORP | $10.2M | 498,673 |
Companies Similar to FLGT
Ranked by quality-profile closeness and shared hedge-fund ownership — not just sector membership.
CERUS CORP
LAKELAND INDUSTRIES INC
Immunocore Holdings plc
PROCEPT BioRobotics Corp
Schrodinger, Inc.
GeneDx Holdings Corp.
BICYCLE THERAPEUTICS PLC
MANNKIND CORP
Similarity is computed from the 8 composite sub-scores and latest-quarter 13F conviction holdings (index-style filers excluded). Refreshed monthly.
More Healthcare Companies
View all Healthcare →Put FLGT on your watchlist
Track score changes the day Fulgent Genetics, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is FLGT a good stock to buy?
13F Pro's AI-powered analysis of Fulgent Genetics, Inc. (FLGT) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for FLGT are available on the FLGT stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. FLGT is classified as a small company.
Which hedge funds own FLGT?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling FLGT. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Fulgent Genetics, Inc.'s investment landscape.